Literature DB >> 27020441

World Health Organization grade II meningiomas.

Charles Champeaux1, Laurence Dunn2.   

Abstract

BACKGROUND: We analyzed WHO grade II meningioma cases to identify factors influencing survival.
MATERIALS AND METHODS: Between January 2000 and August 2015, 206 cases of World Health Organization (WHO) grade II meningioma were operated at our institution. This population underwent a total of 298 surgical resections and 55 patients received a radiotherapy. A Cox multivariate regression was conducted on clinical and histological criteria.
RESULTS: Sixty-four patients were deceased (31.1 %), of which 38 died following the disease progression (18.4 %). Overall survival probability at 1, 5, and 10 years were 95.4 %, 95 % CI [92.5, 98.4]; 84 %, 95 % CI [78.3, 90.2], and 72.9 %, 95 % CI [64.5, 82.4], respectively (Fig. 1a). At the end of the study, only 87 patients (42.2 %) were alive with no tumor residual or recurrence on the last scan. Age at diagnosis (hazard ratio (HR) = 0.31, 95 % CI [0.15, 0.63], p < 0.001), extent of resection (HR = 0.25, 95 % CI [0.12, 0.49], p < 0.001), and tumoral brain invasion (HR = 0.49, 95 % CI [0.25, 0.98], p = 0.040) were independent factors associated with the overall survival. The patients who received radiotherapy did not demonstrate a longer overall survival (p = 0.540).
CONCLUSIONS: WHO grade II meningioma significantly impaired the survival of the patients. In the adjusted Cox regression, a macroscopic gross total resection (Simpson grades 1, 2, and 3), an age below 62 years at diagnosis and the absence of brain invasion were independent factors associated with a longer survival. Radiotherapy may not increase the overall survival after complete or incomplete resection.

Entities:  

Keywords:  Atypical meningioma; Outcome; Prognostic factors; Radiotherapy; Survival; WHO grade II meningioma

Mesh:

Year:  2016        PMID: 27020441     DOI: 10.1007/s00701-016-2771-y

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  4 in total

1.  Atypical meningioma: progression-free survival in 161 cases treated at our institution with surgery versus surgery and radiotherapy.

Authors:  Waseem Masalha; Dieter Henrik Heiland; Pamela Franco; Daniel Delev; Jan Gerrit Haaker; Oliver Schnell; Christian Scheiwe; Juergen Grauvogel
Journal:  J Neurooncol       Date:  2017-10-28       Impact factor: 4.130

2.  Fibulin-2: A Novel Biomarker for Differentiating Grade II from Grade I Meningiomas.

Authors:  Agbolahan A Sofela; David A Hilton; Sylwia Ammoun; Daniele Baiz; Claire L Adams; Emanuela Ercolano; Michael D Jenkinson; Kathreena M Kurian; Mario Teo; Peter C Whitfield; Felix Sahm; C Oliver Hanemann
Journal:  Int J Mol Sci       Date:  2021-01-08       Impact factor: 5.923

Review 3.  Molecular neuropathology of brain-invasive meningiomas.

Authors:  Niklas von Spreckelsen; Christoph Kesseler; Benjamin Brokinkel; Roland Goldbrunner; Arie Perry; Christian Mawrin
Journal:  Brain Pathol       Date:  2022-03       Impact factor: 6.508

4.  Predictors of early progression of surgically treated atypical meningiomas.

Authors:  Karol P Budohoski; James Clerkin; Christopher P Millward; Philip J O'Halloran; Mueez Waqar; Seamus Looby; Adam M H Young; Mathew R Guilfoyle; Diana Fitzroll; Abel Devadass; Kieren Allinson; Michael Farrell; Mohsen Javadpour; Michael D Jenkinson; Thomas Santarius; Ramez W Kirollos
Journal:  Acta Neurochir (Wien)       Date:  2018-06-30       Impact factor: 2.216

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.